# ALTIMMUNE, INC. (ALT) · Edgar & Edgarette company card

> Altimmune, Inc. (ALT) grew revenue 105% in FY2025 to $0 million, operating margin -230461% against a -3.8% median for pharmaceutical preparations, equity 80.3% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1326190 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/ALT) · [JSON](https://www.pops4.com/boards/company/ALT.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $41,000 |
| Revenue growth, 1 year | 105.0% |
| Revenue growth per year | -68.9% |
| Operating margin | -230461.0% (prior year -515860.0%) |
| Net margin | -214861.0% |
| Operating cash flow | −$68M |
| Capital spending | $11,000 |
| Free cash flow | −$68M |
| Cash | $44M |
| Long-term debt | $34M |
| Total assets | $280M |
| Total equity | $225M |
| Equity ÷ assets | 80.3% |
| Return on equity | -39.2% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 0.63 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative (-$67.5M in FY2025); operating loss: a margin of -230461.0% in FY2025; revenue is hard to predict: its 80% range is ±28%

## Edgarette's reading

Exposure: revenue $41K (FY2025), total debt $34.3M. Experience: revenue up 105.0% on the year, down 68.9% a year over 4 years; operating margin -230461.0%, up from -515860.0%. Soundness: equity 80.3% of assets, return on equity -39.2%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $36K and $64K next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -230461.0% against a -3.8% median; growth 105.0% against 13.7%.

Range logged 2026-09-30, receipt 58eed60c5b4ce05c, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 3, latest 2026-10-27 ([filing](https://www.sec.gov/Archives/edgar/data/1326190/000110465926118991/0001104659-26-118991-index.htm))

## Recent filings

- 10-Q · filed 2026-11-12 · [filing](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000070/0001326190-26-000070-index.htm)
- 8-K · filed 2026-11-12 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000067/0001326190-26-000067-index.htm)
- 8-K · filed 2026-10-29 · 2.03 Creation of a Direct Financial Obligation · [filing](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000060/0001326190-26-000060-index.htm)
- 8-K · filed 2026-10-27 · 5.02 Departure or Election of Directors; Appointment of Officers; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1326190/000110465926118991/0001104659-26-118991-index.htm)
- 8-K · filed 2026-09-29 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000056/0001326190-26-000056-index.htm)
- 10-Q · filed 2026-08-12 · [filing](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000052/0001326190-26-000052-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001326190.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1326190

## Cite

POPS4, Edgar & Edgarette: ALTIMMUNE, INC. (ALT) company card, from the company's own SEC filings, accessed 2026-11-14, https://www.pops4.com/boards/company/ALT. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.